



FOR IMMEDIATE RELEASE

CONTACT:

Julie Chase / Angelyn Lechman
Chase Communications
415-433-0100 / 619-203-0961
jchase@chasepr.com /
alechman@chasepr.com

**SUSAN SCHNEIDER, M.D. JOINS SANTEN, INC. AS VICE
PRESIDENT OF CLINICAL AFFAIRS**

NAPA, Calif. -- (May 5, 2007) -- Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical leader Santen Pharmaceutical Co. Ltd., announced today that Susan Schneider, M.D. has joined the company as Vice President, Clinical Affairs.

Formerly a medical director with biotechnology leader Genentech, Inc., Dr. Schneider will be responsible for all clinical research programs at Santen Inc., including the direction, planning, execution, and interpretation of clinical trials.

“With an impressive background in the medical, research and product development arenas, Susan brings a strong skillset to lead our clinical development efforts,” said Adrienne Graves, Ph.D., President and CEO of Santen, Inc. “This era in ophthalmology has produced many exciting new drugs and advances on the horizon. We look forward to Susan’s contributions to Santen’s development of innovative, global ophthalmology products.”

As a board certified ophthalmologist, Dr. Schneider brings with her a diverse medical background that includes experience as a clinician and academician, as well as a clinical scientist. She has served patients, ophthalmology training programs and the community.

While working with Genentech, Dr. Schneider actively participated in monitoring clinical trials, publication strategy and execution, and the FDA submission for ranibizumab (LUCENTIS®), which was approved for the treatment of neovascular age-related macular degeneration in June 2006.

Prior to pursuing a career in biotechnology, Dr. Schneider held full time academic positions in the departments of ophthalmology and pathology at the New York Eye & Ear Infirmary and the University of Cincinnati. In addition, she was employed in a busy ophthalmology private practice in Philadelphia after completing her extensive training.

Dr. Schneider has co-authored and published 28 peer-reviewed articles for a variety of journals, including the *New England Journal of Medicine*, the *American Journal of Ophthalmology* and the *Ophthalmology Journal*.

As an EyeMD, she currently is an active member of the American Academy of Ophthalmology (AAO) and serves as a reviewer on various subcommittees for the Academy's annual meeting. She received an Achievement Award from the AAO in 2004.

Dr. Schneider has presented scientific data at multiple medical meetings and conferences, including the annual meetings of the AAO, the Association for Research in Vision and Ophthalmology (ARVO), the American Society of Cataract and Refractive Surgeons (ASCRS), Ophthalmic Women Leaders (OWL), and the American Association of Ophthalmic Pathologists (AAOP).

Dr. Schneider received her medical degree from the Medical College of Pennsylvania followed by a residency in ophthalmology at the Medical College of Virginia. She has pursued fellowship training in ocular oncology at the Wills Eye Hospital and in ophthalmic pathology at the Wilmer Eye Institute (Johns Hopkins Hospital).

About Santen, Inc.

Santen Inc., based in Napa, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., an \$850 million global company headquartered in Osaka, Japan since 1890. Santen researches, develops and markets ophthalmic products for physicians worldwide. Santen Ltd. has more than a 40% market share for ophthalmic pharmaceuticals in Japan, and has additional subsidiaries in Europe and Asia. For more information, visit www.santeninc.com.

##-##